Karyopharm Therapeutics Inc. (KPTI)
NASDAQ$6.75
Market Cap
$56.81M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
668 of 924
Rank in Industry
380 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
KPTI Insider Trading Activity
KPTI Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,529,038 | 25 | 100 |
Related Transactions
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 0 | $0 | 1 | $3,866 | $-3,866 |
| Mason Michael | EVP, CFO & Treasurer | 0 | $0 | 2 | $5,734 | $-5,734 |
| Poulton Stuart | EVP, Chief Development Officer | 0 | $0 | 2 | $6,782 | $-6,782 |
| Rangwala Reshma | EVP & Chief Medical Officer | 0 | $0 | 1 | $7,943 | $-7,943 |
| Mano Michael | SVP, General Counsel&Secretary | 0 | $0 | 2 | $20,434 | $-20,434 |
| Paulson Richard A. | President and CEO | 0 | $0 | 11 | $36,562 | $-36,562 |
| PAKIANATHAN DEEPIKA | director | 0 | $0 | 6 | $1.45M | $-1.45M |
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with …
Insider Activity of Karyopharm Therapeutics Inc.
Over the last 12 months, insiders at Karyopharm Therapeutics Inc. have bought $0 and sold $1.53M worth of Karyopharm Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Karyopharm Therapeutics Inc. have bought $130,090 and sold $2.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 41,140 shares for transaction amount of $49,985 was made by BOHLIN GAREN G (director) on 2023‑09‑12.
List of Insider Buy and Sell Transactions, Karyopharm Therapeutics Inc.
| 2025-03-04 | Sale | Mano Michael | SVP, General Counsel&Secretary | 2,793 0.0333% | $6.29 | $17,568 | +8.24% | |
| 2025-02-18 | Sale | Poulton Stuart | EVP, Chief Development Officer | 5,914 0.0048% | $0.63 | $3,726 | -19.52% | |
| 2025-02-04 | Sale | Paulson Richard A. | President and CEO | 4,099 0.0034% | $0.65 | $2,664 | -5.48% | |
| 2025-01-06 | Sale | Paulson Richard A. | President and CEO | 4,055 0.0031% | $0.78 | $3,175 | -25.00% | |
| 2024-12-04 | Sale | Paulson Richard A. | President and CEO | 3,620 0.003% | $0.81 | $2,932 | -18.29% | |
| 2024-11-05 | Sale | Paulson Richard A. | President and CEO | 3,675 0.0029% | $0.91 | $3,346 | -20.57% | |
| 2024-10-04 | Sale | Paulson Richard A. | President and CEO | 3,607 0.0036% | $0.88 | $3,172 | -20.96% | |
| 2024-09-04 | Sale | Paulson Richard A. | President and CEO | 3,667 0.003% | $0.72 | $2,647 | +2.43% | |
| 2024-09-04 | Sale | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 5,356 0.0044% | $0.72 | $3,866 | +2.43% | |
| 2024-09-04 | Sale | Mason Michael | EVP, CFO & Treasurer | 7,050 0.0057% | $0.72 | $5,089 | +2.43% | |
| 2024-09-04 | Sale | Mano Michael | SVP, General Counsel&Secretary | 3,971 0.0032% | $0.72 | $2,866 | +2.43% | |
| 2024-08-06 | Sale | Paulson Richard A. | President and CEO | 3,608 0.0032% | $0.93 | $3,355 | -10.71% | |
| 2024-07-30 | Sale | Poulton Stuart | EVP, Chief Development Officer | 2,883 0.0023% | $1.06 | $3,056 | -28.11% | |
| 2024-07-05 | Sale | Paulson Richard A. | President and CEO | 3,616 0.0025% | $0.85 | $3,077 | -5.05% | |
| 2024-06-07 | Sale | PAKIANATHAN DEEPIKA | director | 2,240 0.0018% | $0.95 | $2,130 | -16.88% | |
| 2024-06-06 | Sale | PAKIANATHAN DEEPIKA | director | 118,452 0.096% | $0.98 | $116,415 | -17.85% | |
| 2024-06-05 | Sale | PAKIANATHAN DEEPIKA | director | 468,044 0.3619% | $0.96 | $448,480 | -19.57% | |
| 2024-06-04 | Sale | Paulson Richard A. | President and CEO | 3,592 0.0033% | $0.99 | $3,556 | -13.73% | |
| 2024-06-04 | Sale | Mason Michael | EVP, CFO & Treasurer | 652 0.0006% | $0.99 | $645 | -13.73% | |
| 2024-06-04 | Sale | PAKIANATHAN DEEPIKA | director | 341,040 0.2976% | $0.95 | $324,704 | -13.73% |
Total: 371
*Gray background shows transactions not older than one year
Insider Historical Profitability
2.08%
| PAKIANATHAN DEEPIKA | director | 0 0% | $0 | 5 | 7 | +36.66% |
| Frenkel Ran | EVP, Chief Dev. Officer | 168290 1.9996% | $1.14M | 2 | 9 | <0.0001% |
| Shah Jatin | EVP, Chief Medical Officer | 129450 1.5381% | $873,787.50 | 1 | 6 | <0.0001% |
| Brannelly Paul | SVP, FINANCE & ADMIN, TREAS | 66136 0.7858% | $446,418.00 | 3 | 0 | +28.23% |
| BOHLIN GAREN G | director | 45140 0.5364% | $304,695.00 | 2 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$6,787,959 | 35 | 49.84% | $60.62M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$144,247,213 | 29 | 10.15% | $64.24M | |
$2,239,226 | 28 | 3.41% | $63.36M | |
$26,736,140 | 20 | -18.64% | $54.85M |
KPTI Institutional Investors: Active Positions
| Increased Positions | 34 | +28.81% | 681,637 | +17.18% |
| Decreased Positions | 44 | -37.29% | 587,793 | -14.82% |
| New Positions | 14 | New | 191,230 | New |
| Sold Out Positions | 21 | Sold Out | 122,214 | Sold Out |
| Total Postitions | 108 | -8.47% | 4M | +2.37% |
KPTI Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $4,057.00 | 6.38% | 510,324 | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $3,350.00 | 5.27% | 421,344 | +133,340 | +46.3% | 2024-12-31 |
| Palo Alto Investors Lp | $2,601.00 | 4.09% | 327,150 | -13,013 | -3.83% | 2024-12-31 |
| Blackrock, Inc. | $1,998.00 | 3.14% | 251,271 | +8,700 | +3.59% | 2024-12-31 |
| Morgan Stanley | $1,862.00 | 2.93% | 234,224 | +225,980 | +2,741.14% | 2024-12-31 |
| Citadel Advisors Llc | $1,645.00 | 2.59% | 206,922 | 0 | 0% | 2024-12-31 |
| Marshall Wace, Llp | $1,273.00 | 2% | 160,102 | +21,280 | +15.33% | 2024-12-31 |
| Catalio Capital Management, Lp | $1,237.00 | 1.95% | 155,633 | +155,633 | New | 2024-12-31 |
| Eversept Partners, Lp | $1,107.00 | 1.74% | 139,257 | -230,620 | -62.35% | 2024-12-31 |
| Avidity Partners Management Lp | $1,070.00 | 1.68% | 134,573 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.